NEXTBio Capital Management LP

CIK 0002038158 · AUSTIN, TX · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

NEXTBio Capital Management LP reported 22 positions worth $217.4M as of June 30, 2026 (13F filed August 14, 2026). Largest holding: PTGX (12.4%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$217.4M
2026 Q2
Positions
22
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
77.7%
Est. Net Flow (Q)
2026 Q2
10 / 22 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1PTGXPROTAGONIST THERAPEUTICS INCSH$26.9M12.37%219,333
2STTKSHATTUCK LABS INCSH$25.9M11.90%3,727,348
3CMPSCOMPASS PATHWAYS PLCSH$25.1M11.56%1,775,759
4GPCRSTRUCTURE THERAPEUTICS INCSH$16.8M7.71%312,496
5VORVOR BIOPHARMA INCSH$16.4M7.53%889,164
6RYTMRHYTHM PHARMACEUTICALS INCSH$14.6M6.73%131,758
7PVLAPALVELLA THERAPEUTICS INC NESH$13.7M6.32%89,909
8XENEXENON PHARMACEUTICALS INCSH$11.1M5.09%183,225
9ZBIOZENAS BIOPHARMA INCSH$10.8M4.98%426,736
10ORICORIC PHARMACEUTICALS INCSH$7.6M3.52%706,124

The free plan shows the top 10 positions. The remaining 12 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does NEXTBio Capital Management LP hold as of Q2 2026?

NEXTBio Capital Management LP reported 22 positions worth $217.4M in its Q2 2026 13F filing. Largest positions: PTGX (12.4%), STTK (11.9%), CMPS (11.6%), GPCR (7.7%) and VOR (7.5%).

What did NEXTBio Capital Management LP buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did NEXTBio Capital Management LP sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.